亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Nebulised ALX-0171 for respiratory syncytial virus lower respiratory tract infection in hospitalised children: a double-blind, randomised, placebo-controlled, phase 2b trial

医学 安慰剂 双盲 下呼吸道感染 随机对照试验 呼吸道感染 呼吸系统 儿科 内科学 麻醉 替代医学 病理
作者
Steve Cunningham,Pedro A. Piedra,Federico Martinón‐Torres,Henryk Szymański,Benedicte Brackeva,Evelyne J. Dombrecht,Laurent Detalle,Carmen Fleurinck,Steve Cunningham,Pedra A Piedra,Stijn L. Verhulst,Inge Matthijs,Marijke Proesmans,Tessa Goetghebuer,Miroslava Bosheva,S Dosev,Olga Nikolova,Petranka Chakarova,Elba Wu Hupat,Juan Gonzalo Mesa-Monsalve
出处
期刊:The Lancet Respiratory Medicine [Elsevier BV]
卷期号:9 (1): 21-32 被引量:132
标识
DOI:10.1016/s2213-2600(20)30320-9
摘要

Background Respiratory syncytial virus (RSV) is the most common cause of severe lower respiratory tract infection, with a high global health burden. There are no effective treatments available. ALX-0171 is a novel trivalent Nanobody with antiviral properties against RSV. We aimed to assess the safety and antiviral activity of nebulised ALX-0171 in children admitted to hospital with RSV lower respiratory tract infection. Methods This double-blind, randomised, placebo-controlled, phase 2b trial was done in 50 hospital paediatric departments across 16 countries. Previously healthy children aged between 28 days to younger than 24 months who were admitted to hospital with RSV acute severe lower respiratory tract infection were randomly assigned in three sequential safety cohorts (3:1) to receive nebulised ALX-0171 (cohort 1 received 3 mg/kg, cohort 2 received 6 mg/kg, and cohort 3 received 9 mg/kg) or placebo once daily for 3 days using web-based randomisation in the sequential safety part (first block size 12, subsequently four). In a parallel part of the study, participants (cohort 4) were randomly assigned (parallel 1:1:1:1) to receive nebulised ALX-0171 3 mg/kg, 6 mg/kg, 9 mg/kg, or placebo (blocks of eight by restricted randomisation). Study drug masking was by two consecutive nebulisations (each either ALX-0171 or placebo) depending on assigned treatment group. The primary outcome was to evaluate time for the RSV viral load to drop to below quantifiable limit, measured by plaque assay on mid-turbinate nasal swabs. Safety, clinical efficacy, pharmacokinetics, viral load by RT-qPCR, and immunogenicity were secondary outcomes. Analysis, including of the primary outcome, was by modified intention to treat (participants receiving at least one dose of study drug as assigned), and safety was assessed in all children who received at least one administration of study drug, as treated. This trial is registered with EudraCT, 2016-001651-49. Findings Between Jan 10, 2017, and April 26, 2018, 175 children (median age 4·8 months [IQR 2·0–10·8]), received at least one dose of study drug (45 received 3 mg/kg of ALX-0171, 43 received 6 mg/kg of ALX-0171, 45 received 9 mg/kg of ALX-0171, and 42 received placebo; the modified intention-to-treat population) commencing at a mean 3·3 days (SD 1·1) from symptom onset. Median time for the viral load to drop to below quantifiable limit on plaque assay was significantly faster for the 3 mg/kg group (median 14·2 h [IQR 5·0–28·0]), 6 mg/kg group (5·1 h [4·7–28·5]), and 9 mg/kg group (5·1 h [4·6–5·9]) than the placebo group (46·1 h [25·2–116·7]; hazard ratio [HR] all ALX-0171 groups vs placebo 2·6 [1·7–3·9]; p<0·0001). Median time for the viral load to drop below quantification limit with RT-qPCR was 95·9 h (IQR 26·7 to not estimable) for the placebo group (n=35) versus 49·4 h (25·1 to 351·4) for all ALX-0171 groups (n=118). Clinical outcomes were not improved by ALX-0171 compared with placebo, with no difference in time to clinical response (oxygen saturation >92% for 4 h in room air and adequate oral feeding) in ALX-0171 groups and the placebo group (median 43·8 h [IQR 21·7–68·5] vs 47·9 h [22·5–76·4]; HR 1·1 [95% CI 0·8–1·6]) or change in the global severity score from baseline to 5 h post-dose on day 2 (−4 [IQR −6 to −2] vs −4 [–6 to −1]; difference in least-squares mean −0·45 [95% CI −1·39 to 0·49]). Serum concentrations of ALX-0171 on day 2 exceeded the concentration estimated to give full RSV neutralisation in the lung at 6 mg/kg and 9 mg/kg doses. Treatment-emergent antidrug antibodies were detected at day 14 in 46 (34%) of 135 patients who received ALX-0171 and ten (26%) of 39 patients who received placebo. Serious adverse events were reported in five (13%) of 40 children in the placebo group and ten (7%) of 135 children in all ALX-0171 groups, leading to study drug discontinuation in three children (two in the 3 mg/kg group and one in the 6 mg/kg group). 13 of 15 serious adverse events (three of four in the 3 mg/kg group, two of three in the 6 mg/kg group, three of three in the 9 mg/kg group, and five of five in the placebo group) were related to worsening respiratory status, and none were considered to be related to the study drug. Interpretation Antivirals against RSV might be unable to improve clinical course once RSV lower respiratory tract infection is established. Future studies of RSV antivirals should focus on earlier intervention and more precise measurement of objective outcomes before the onset of significant lower respiratory tract inflammation. Funding Ablynx, a Sanofi Company.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
华仔的应助被爱学习的doge采纳,获得10
2秒前
李爱国的应助被爱学习的doge采纳,获得50
2秒前
2秒前
赘婿的应助被爱学习的doge采纳,获得10
3秒前
小马甲的应助被爱学习的doge采纳,获得10
3秒前
3秒前
3秒前
Owen的应助被爱学习的doge采纳,获得10
3秒前
斯文败类的应助被爱学习的doge采纳,获得30
4秒前
华仔的应助被爱学习的doge采纳,获得10
4秒前
9秒前
10秒前
桐桐的应助被爱学习的doge采纳,获得10
11秒前
11秒前
11秒前
共享精神的应助被爱学习的doge采纳,获得10
11秒前
顾矜的应助被爱学习的doge采纳,获得10
11秒前
Owen的应助被爱学习的doge采纳,获得10
11秒前
molihuakai的应助被爱学习的doge采纳,获得10
11秒前
JamesPei的应助被爱学习的doge采纳,获得10
11秒前
英姑的应助被爱学习的doge采纳,获得10
11秒前
25秒前
Ccccn完成签到,获得积分10
30秒前
Voiceless发布了新的文献求助10
33秒前
34秒前
满意的平凡完成签到,获得积分10
39秒前
伶俐的秀发完成签到,获得积分10
40秒前
ChenYQ完成签到,获得积分10
1分钟前
苹果完成签到 ,获得积分10
1分钟前
殷勤的半凡完成签到,获得积分10
1分钟前
耍酷的手套完成签到,获得积分10
1分钟前
1分钟前
1分钟前
充电宝的应助被爱学习的doge采纳,获得10
1分钟前
1分钟前
1分钟前
1分钟前
orixero的应助被爱学习的doge采纳,获得10
1分钟前
隐形曼青的应助被爱学习的doge采纳,获得10
1分钟前
在水一方的应助被爱学习的doge采纳,获得10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179924
求助须知:如何正确求助?哪些是违规求助? 9570159
关于积分的说明 21808379
捐赠科研通 7775767
什么是DOI,文献DOI怎么找? 3433193
关于科研通互助平台的介绍 2557347
邀请新用户注册赠送积分活动 2478918